Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 779 of 6351
-
New combo therapy targets Hard-to-Cure leukemia
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and has a mutation in th…
Phase 1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New CAR-T therapy aims to tackle tough blood cancers
Disease control Recruiting nowThis is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells. This study will …
Phase 1 • Sponsor: University of Utah • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a cold sore virus treatment save ICU pneumonia patients?
Disease control Recruiting nowAlmost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can't get rid of them for the rest of her/his life. For the most part, the viruses are in a dormant state. Only when the immune system is weakened, f…
Phase 3 • Sponsor: Jena University Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo aims to stop rare Cancer's return after surgery
Disease control Recruiting nowIn this study, 60 patients with HER2 overexpression UTUC with high-risk recurrence factors after radical surgery were proposed to be enrolled, and were assigned to Cohort I (receiving adjuvant therapy group) and Cohort II (refusing to receive adjuvant therapy group) according to …
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New light therapy targets deadly brain tumors during surgery
Disease control OngoingThe primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 75 with newly diagnosed glioblastoma. This treat…
Phase 1/2 • Sponsor: Hemerion Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New Four-Drug cocktail aims to crush resistant myeloma
Disease control Recruiting nowThe investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard…
Phase 2 • Sponsor: Benjamin T Diamond, MD • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill combo shows promise for Tough-to-Treat breast cancer
Disease control OngoingThe purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started …
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New injection every 8 weeks shows promise for thyroid eye disease
Disease control OngoingPhase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Phase 2 • Sponsor: Tourmaline Bio, Inc., a Novartis Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New immunotherapy combo may save bladders in cancer patients
Disease control OngoingThis is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment
Phase 2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a High-Tech nebulizer tame severe asthma attacks faster?
Disease control Recruiting nowAcute exacerbation of asthma represents an acute or sub-acute worsening in symptoms and lung function in patients with asthma. It is characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing, or chest tightness. It is a common diagnosis in patien…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for advanced prostate cancer: PET-Guided radiation may delay progression
Disease control Recruiting nowThis phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate cancer that is sensitive to androgen-depri…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could hormone pills replace surgery for some early breast cancers?
Disease control Recruiting nowThe goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control …
Phase 2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New triple-drug cocktail takes on hard-to-treat head and neck cancer
Disease control Recruiting nowThe purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The na…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for kids with rare seizure disorder: vitamin B6 therapy in final testing phase
Disease control Recruiting nowThe proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made com…
Phase 3 • Sponsor: Medicure • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug before surgery may keep prostate cancer at bay
Disease control OngoingThis study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Gene therapy injection could ease chronic bladder pain
Disease control Recruiting nowTo evaluate the efficacy and safety of Neovasculgen in interstitial cystitis and the prevention of secondary bladder shrinkage with a decrease in its volume.
Phase 2/3 • Sponsor: JSC NextGen • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Personalized web therapy may curb teen substance use and mental health struggles
Disease control CompletedOnly a small fraction of youth who are beginning to experience behavioral health problems and use alcohol or illicit drugs receive needed treatment services due to the lack of accessible, effective early intervention resources. The goal of this clinical trial is to compare a pers…
Sponsor: Oregon Research Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could a new pill break up Alzheimer's brain clumps?
Disease control CompletedAlzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour. The company PRInnovation is developing a new treatment for Alzheimer's disease, called PRI-002.…
Phase 2 • Sponsor: PRInnovation GmbH • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Heated chemotherapy shows promise for advanced pancreatic cancer
Disease control Recruiting nowThis phase II trial studies the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with pancreatic cancer that has spread to the internal abdominal area (peritoneal metastasis). Chemotherapy drugs, such as nab-paclitaxel and cisplatin, work in diffe…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Mind over matter: could mental training strengthen MS hands?
Symptom relief CompletedThis randomized controlled trial investigated the effects of sequential laterality, motor imagery, and mental rotation training in individuals with relapsing-remitting multiple sclerosis. Both groups received conventional physiotherapy, while the intervention group received struc…
Sponsor: Abant Izzet Baysal University • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC